Neurohormonal activation and pharmacological inhibition in pulmonary arterial hypertension and related right ventricular failure

Heart Failure Reviews

Volumn 21, Issue 5, 2016, Pages 539-547

  Ameri, Pietro ^a,c   Bertero, Edoardo ^a   Meliota, Giovanni ^a   Cheli, Martino ^a,b   Canepa, Marco ^a   Brunelli, Claudio ^a   Balbi, Manrico ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b G GASLINI INSTITUTE   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

ACE inhibitor; Aldosterone; Angiotensin; Neurohormonal; Pulmonary arterial hypertension; Right ventricle; blocker

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ADRENERGIC SYSTEM; ANIMAL; COMPLICATION; DRUG EFFECTS; HEART RIGHT VENTRICLE FUNCTION; HUMAN; PATHOPHYSIOLOGY; PULMONARY HYPERTENSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; HUMANS; HYPERTENSION, PULMONARY; RENIN-ANGIOTENSIN SYSTEM; SYMPATHETIC NERVOUS SYSTEM; VENTRICULAR DYSFUNCTION, RIGHT;

EID: 84971657465     PISSN: 13824147     EISSN: 15737322     Source Type: Journal    
DOI: 10.1007/s10741-016-9566-3     Document Type: Article

References (50)

1. Galiè N, Humbert M, Vachiery JL, Gibbs S et al (2016) 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 37(1):67–119. doi:10.1093/eurheartj/ehv317
2. Abraham WT, Raynolds MV, Gottschall B, Badesch DB, Wynne KM, Groves BM, Lowes BD, Bristow MR, Perryman MB, Voelkel NF (1995) Importance of angiotensin-converting enzyme in pulmonary hypertension. Cardiology 10(Suppl 1):9–15
3. Bogaard HJ, Abe K, Vonk Noordegraaf A, Voelkel NF (2009) The right ventricle under pressure: cellular and molecular mechanisms of right-heart failure in pulmonary hypertension. Chest 20(135):794–804. doi:10.1378/chest.08-0492
4. Florea VG, Cohn JN (2014) The autonomic nervous system and heart failure. Circ Res 114:1815–1826. doi:10.1161/CIRCRESAHA.114.302589
5. Bristow MR, Minobe W, Rasmussen R, Larrabee P, Skerl L, Klein JW, Anderson FL et al (1992) β-adrenergic neuroeffector abnormalities in the failing human heart are produced by local, rather than systemic mechanisms. J Clin Invest 89(3):803–815
6. Sakamaki F, Satoh T, Nagaya N, Kyotani S, Oya H, Nakanishi N, Kuribayashi S, Ishida Y (2000) Correlation between severity of pulmonary arterial hypertension and 123I-Metaiodobenzylguanidine left ventricular imaging. J Nucl Med 41:1127–1133
7. Haneda T, Nakajima T, Shirato K et al (1983) Effects of oxygen breathing on pulmonary vascular input impedance in patients with pulmonary hypertension. Chest 83:520–527
8. Richards AM, Ikram H, Crozier IG et al (1990) Ambulatory pulmonary arterial pressure in primary pulmonary hypertension: variability, relation to systemic arterial pressure, and plasma catecholamines. Br Heart J 63:103–108
9. Velez-Roa S, Ciarka A, Najem B, Vachiery JL, Naeije R, van de Borne P (2004) Increased sympathetic nerve activity in pulmonary artery hypertension. Circulation 10(10):1308–1312. doi:10.1161/01.CIR.0000140724.90898.D3
10. Sanyal SN, Ono K (2002) Derangement of autonomic nerve control in rat with right ventricular failure. Pathophysiology 8(3):197–203
11. Fauchier L, Babuty D, Melin A, Bonnet P, Cosnay P, Fauchier JP (2004) Heart rate variability in severe right or left heart failure: the role of pulmonary hypertension and resistances. Eur J Heart Fail 6(2):181–185
12. Ciarka A, Doan V, Velez-Roa S, Naeije R, van de Borne P (2010) Prognostic significance of sympathetic nervous system activation in pulmonary arterial hypertension. Am J Respir Crit Care Med 181(11):1269–1275. doi:10.1164/rccm.200912-1856OC
13. Ponikowski P, Chua TP, Piepoli M, Ondusova D, Webb-Peploe K, Harrington D, Anker SD, Volterrani M, Colombo R, Mazzuero G et al (1997) Augmented peripheral chemosensitivity as a potential input to baroreflex impairment and autonomic imbalance in chronic heart failure. Circulation 96:2586–2594
14. Notarius CF, Atchison DJ, Floras JS (2001) Impact of heart failure and exercise capacity on sympathetic response to handgrip exercise. Am J Physiol Heart Circ Physiol 280:H969–H976
15. Grassi G, Seravalle G, Cattaneo BM, Lanfranchi A, Vailati S, Giannattasio C, Del BA, Sala C, Bolla GB, Pozzi M (1995) Sympathetic activation and loss of reflex sympathetic control in mild congestive heart failure. Circulation 92:3206–3211
16. Wensel R, Opitz CF, Anker SD, Winkler J, Hoffken G, Kleber FX, Sharma R, Hummel M, Hetzer R, Ewert R (2002) Assessment of survival in patients with primary pulmonary hypertension: importance of cardio-pulmonary exercise testing. Circulation 106:319–324
17. De Man FS, Handoko ML, van Ballegoij JJ, Schalij I, Bogaards SJ, Postmus PE, van der Velden J, Westerhof N, Paulus WJ, Vonk-Noordegraaf A (2012) Bisoprolol delays progression towards right heart failure in experimental pulmonary hypertension. Circ Heart Fail 5:97–105. doi:10.1161/CIRCHEARTFAILURE.111.964494
18. Forfia PR, Mathai SC, Fisher MR, Housten-Harris T, Hemnes AR, Champion HC, Girgis RE, Hassoun PM (2008) Hyponatremia predicts right heart failure and poor survival in pulmonary arterial hypertension. Am J Respir Crit Care Med 177:1364–1369. doi:10.1164/rccm.200712-1876OC
19. Orte C, Polak JM, Haworth SG, Yacoub MH, Morrell NW (2000) Expression of pulmonary vascular angiotensin-converting enzyme in primary and secondary plexiform pulmonary hypertension. J Pathol 192:379–384
20. Rondelet B, Kerbaul F, Van Beneden R, Hubloue I, Huez S, Fesler P, Remmelink M, Brimioulle S, Salmon I, Naeije R (2005) Prevention of pulmonary vascular remodeling and of decreased BMPR-2 expression by losartan therapy in shunt-induced pulmonary hypertension. Am J Physiol Heart Circ Physiol 289:H2319–H2324
21. Rouleau JL, Kapuku G, Pelletier S, Gosselin H, Adam A, Gagnon C, Lambert C, Meloche S (2001) Cardioprotective effects of ramipril and losartan in right ventricular pressure overload in the rabbit: importance of kinins and influence on angiotensin II type 1 receptor signaling pathway. Circulation 104:939–944
22. Maron BA, Zhang YY, White K, Chan SY, Handy DE, Mahoney CE, Loscalzo J, Leopold JA (2012) Aldosterone inactivates the endothelin-B receptor via a cysteinyl thiol redox switch to decrease pulmonary endothelial nitric oxide levels and modulate pulmonary arterial hypertension. Circulation 126(8):963–974. doi:10.1161/CIRCULATIONAHA.112.094722
23. Zisman LS, Asano K, Dutcher DL, Ferdensi A, Robertson AD, Jenkin M, Bush EW, Bohlmeyer T, Perryman MB, Bristow MR (1998) Differential regulation of cardiac angiotensin converting enzyme binding sites and AT1 receptor density in the failing human heart. Circulation 98(17):1735–1741
24. Abraham WT, Raynolds MV, Badesch DB, Wynne KM, Groves BM, Roden RL, Robertson AD, Lowes BD, Zisman LS, Voelkel NF, Bristow MR, Perryman MB (2003) Angiotensin-converting enzyme DD genotype in patients with primary pulmonary hypertension: increased frequency and association with preserved haemodynamics. J Renin Angiotensin Aldosterone Syst 4:27–30
25. Iusuf D, Henning RH, van Gilst WH, Roks AJ (2008) Angiotensin-(1–7): pharmacological properties and pharmacotherapeutic perspectives. Eur J Pharmacol 585:303–312. doi:10.1016/j.ejphar.2008.02.090
26. Shenoy V, Ferreira AJ, Qi Y, Fraga-Silva RA, Diez-Freire C, Dooies A, Jun JY, Sriramula S, Mariappan N, Pourang D et al (2010) The angiotensin-converting enzyme 2/angiogenesis-(1–7)/Mas axis confers cardiopulmonary protection against lung fibrosis and pulmonary hypertension. Am J Respir Crit Care Med 182:1065–1072. doi:10.1164/rccm.200912-1840OC
27. Bogaard HJ, Natarajan R, Mizuno S et al (2010) Adrenergic receptor blockade reverses right heart remodeling and dysfunction in pulmonary hypertensive rats. Am J Respir Crit Care Med 182:652–660. doi:10.1164/rccm.201003-0335OC
28. Mochizuki M, Yano M, Oda T, Tateishi H, Kobayashi S, Yamamoto T, Ikeda Y, Ohkusa T, Ikemoto N, Matsuzaki M (2007) Scavenging free radicals by low-dose carvedilol prevents redox-dependent Ca21 leak via stabilization of ryanodine receptor in heart failure. J Am Coll Cardiol 49:1722–1732
29. Kurum T, Tatli E, Yuksel M (2007) Effects of carvedilol on plasma levels of pro-inflammatory cytokines in patients with ischemic and nonischemic dilated cardiomyopathy. Tex Heart Inst J 34:52–59
30. Voelkel NF, McMurtry IF, Reeves JT (1980) Chronic propranolol treatment blunts right ventricular hypertrophy in rats at high altitude. J Appl Physiol 48:473–478
31. Tual L, Morel OE, Favret F, Fouillit M, Guernier C, Buvry A, Germain L, Dhonneur G, Bernaudin JF, Richalet JP (2006) Carvedilol inhibits right ventricular hypertrophy induced by chronic hypobaric hypoxia. Pflugers Arch 452:371–379
32. Ishikawa M, Sato N, Asai K, Takano T, Mizuno K (2009) Effects of a pure alpha/beta-adrenergic receptor blocker on monocrotaline-induced pulmonary arterial hypertension with right ventricular hypertrophy in rats. Circ J 73:2337–2341
33. Fujio H, Nakamura K, Matsubara H, Kusano KF, Miyaji K, Nagase S, Ikeda T, Ogawa A, Ohta-Ogo K, Miura D et al (2006) Carvedilol inhibits proliferation of cultured pulmonary artery smooth muscle cells of patients with idiopathic pulmonary arterial hypertension. J Cardiovasc Pharmacol 47:250–255
34. Perros F, Ranchoux B, Izikki M, Bentebbal S, Happé C, Antigny F, Jourdon P, Dorfmüller P, Lecerf F, Fadel E, Simonneau G, Humbert M, Bogaard HJ, Eddahibi S (2015) Nebivolol for improving endothelial dysfunction, pulmonary vascular remodeling, and right heart function in pulmonary hypertension. J Am Coll Cardiol 65(7):668–680. doi:10.1016/j.jacc.2014.11.050
35. Lowes BD, Minobe W, Abraham WT, Rizeq MN, Bohlmeyer TJ, Quaife RA, Roden RL, Dutcher DL, Robertson AD, Voelkel NF, Badesch DB, Groves BM, Gilbert EM, Bristow MR (1997) Changes in gene expression in the intact human heart: downregulation of alpha-myosin heavy chain in hypertrophied, failing ventricular myocardium. J Clin Invest 100:2315–2324
36. Gomez-Arroyo J, Mizuno S, Szczepanek K, Van Tassell B, Natarajan R, dos Remedios CG, Drake JI, Farkas L, Kraskauskas D, Wijesinghe DS, Chalfant CE, Bigbee J, Abbate A, Lesnefsky EJ, Bogaard HJ, Voelkel NF (2013) Metabolic gene remodeling and mitochondrial dysfunction in failing right ventricular hypertrophy due to pulmonary arterial hypertension. Circ Heart Fail 6(1):136–144. doi:10.1161/CIRCHEARTFAILURE.111.966127
37. Wang L, Li W, Yang Y, Wu W, Cai Q, Ma X, Xiong C, He J, Fang W (2015) Quantitative assessment of right ventricular glucose metabolism in idiopathic pulmonary arterial hypertension patients: a longitudinal study. Eur Heart J Cardiovasc Imaging. doi:10.1093/ehjci/jev297
38. Drake JI, Gomez-Arroyo J, Dumur CI, Kraskauskas D, Natarajan R, Bogaard HJ, Fawcett P, Voelkel NF (2013) Chronic carvedilol treatment partially reverses the right ventricular failure transcriptional profile in experimental pulmonary hypertension. Physiol Genomics 45:449–461. doi:10.1152/physiolgenomics.00166.2012
39. Lowes BD, Gilbert EM, Abraham WT, Minobe WA, Larrabee P, Ferguson D, Wolfel EE, Lindenfeld J, Tsvetkova T, Robertson AD, Quaife RA, Bristow MR (2002) Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. N Engl J Med 346:1357–1365
40. Okada M, Kikuzuki R, Harada T, Hori Y, Yamawaki H, Hara Y (2008) Captopril attenuates matrix metalloproteinase-2 and -9 in monocrotaline-induced right ventricular hypertrophy in rats. J Pharmacol Sci 108(4):487–494
41. Okada M, Harada T, Kikuzuki R, Yamawaki H, Hara Y (2009) Effects of telmisartan on right ventricular remodeling induced by monocrotaline in rats. J Pharmacol Sci 111:193–200
42. Provencher S, Herve P, Jais X, Lebrec D, Humbert M, Simonneau G, Sitbon O (2006) Deleterious effects of beta-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension. Gastroenterology 130(1):120–126
43. Thenappan T, Roy SS, Duval S, Glassner-Kolmin C, Gomberg-Maitland M (2014) β-blocker therapy is not associated with adverse outcomes in patients with pulmonary arterial hypertension: a propensity score analysis. Circ Heart Fail 7(6):903–910
44. Bandyopadhyay D, Bajaj N, Zein J, Minai OA, Dweik RA (2015) Outcomes of β-blocker use in pulmonary arterial hypertension: a propensity matched analysis. Eur Respir J 46(3):750–760
45. So PP, Davies RA, Chandy G, Stewart D, Beanlands RS, Haddad H, Pugliese C, Mielniczuk LM (2012) Usefulness of beta-blocker therapy and outcomes in patients with pulmonary arterial hypertension. Am J Cardiol 109(10):1504–1509
46. Moretti C, Grosso Marra W, D’Ascenzo F, Omedè P, Cannillo M, Libertucci D, Fusaro E, Meynet I, Giordana F, Salera D, Annone U, Chen SL, Marra S, Gaita F (2015) Beta blocker for patients with pulmonary arterial hypertension: a single center experience. Int J Cardiol 184(1):528–532
47. Grinnan D, Bogaard HJ, Grizzard J, Van Tassell B, Abbate A, DeWilde C, Priday A, Voelkel NF (2014) Treatment of group I pulmonary arterial hypertension with carvedilol is safe. Am J Respir Crit Care Med 189(12):1562–1564
48. Maron BA, Waxman AB, Opotowsky AR, Gillies H, Blair C, Aghamohammadzadeh R, Loscalzo J, Leopold JA (2013) Effectiveness of spironolactone plus ambrisentan for treatment of pulmonary arterial hypertension (from the [ARIES] study 1 and 2 trials). Am J Cardiol 112(5):720–725. doi:10.1016/j.amjcard.2013.04.051
49. Rich S, Martinez J, Lam W, Rosen KM (1982) Captopril as treatment for patients with pulmonary hypertension. Problem of variability in assessing chronic drug treatment. Br Heart J 48(3):272–277
50. Leier CV, Bambach D, Nelson S, Hermiller JB, Huss P, Magorien RD, Unverferth DV (1983) Captopril in primary pulmonary hypertension. Circulation 67(1):155–161